AI assistant
SCYNEXIS INC — Director's Dealing 2014
May 2, 2014
34648_dirs_2014-05-02_3cf8b8a0-1f86-4541-b158-1662d1ee7950.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: SCYNEXIS INC (SCYX)
CIK: 0001178253
Period of Report: 2014-05-02
Reporting Person: ALTA BIOPHARMA PARTNERS II LP (10% Owner)
Reporting Person: ALTA BIOPHARMA MANAGEMENT II LLC (10% Owner)
Reporting Person: ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC (10% Owner)
Reporting Person: CHAMPSI FARAH (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock Warrant (right to buy) | $0.20 | 2016-12-06 | Common Stock (4551) | Direct | |
| Common Stock Warrant (right to buy) | $0.20 | 2017-05-14 | Common Stock (4551) | Direct | |
| Common Stock Warrant (right to buy) | $0.20 | 2018-12-10 | Common Stock (82454) | Direct | |
| Common Stock Warrant (right to buy) | $0.20 | 2016-12-06 | Common Stock (174) | Indirect | |
| Common Stock Warrant (right to buy) | $0.20 | 2017-05-14 | Common Stock (174) | Indirect | |
| Common Stock Warrant (right to buy) | $0.20 | 2018-12-10 | Common Stock (3033) | Indirect | |
| Series C Preferred Stock | $ | Common Stock (161238) | Direct | ||
| Series C Preferred Stock | $ | Common Stock (5931) | Indirect | ||
| Series D-1 Preferred Stock | $ | Common Stock (50239) | Direct | ||
| Series D-1 Preferred Stock | $ | Common Stock (1848) | Indirect | ||
| Series D-2 Preferred Stock | $ | Common Stock (69476) | Direct | ||
| Series D-2 Preferred Stock | $ | Common Stock (2642) | Indirect |
Footnotes
F1: Farah Champsi (known as the "Principal") is the managing director of Alta BioPharma Management II, LLC ("ABM II") (which is the general partner of Alta BioPharma Partners II, L.P. ("ABP II")), and manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBP II"). As managing director and manager of such entities, Ms. Champsi may be deemed to have voting and investment power for the shares held by ABP II and AEBP II. The Principal disclaims beneficial ownership of all such shares held by ABP II and AEBP II, except to the extent of her proportionate pecuniary interests therein.
F2: These securities are held by AEBP II.
F3: Each of the Series C Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-3.536 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
F4: Each of the Series D-1 Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-20.4 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
F5: Each of the Series D-2 Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-20.4 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.